Methods and compositions for modulating conjunctival goblet cells
AssigneeThe Schepens Eye Research Institute, Inc.
InventorDarlene Dartt
Life of this patent
Estimating the term…
Abstract
The present invention relates to conjunctival goblet cell proliferation and secretions. The present invention also relates to compositions that can modulate conjunctival goblet cell proliferation and secretions. The present invention also relates to galectins, PDGF, bFGF, and the regulation of goblet cells.
Claims16
An ophthalmic composition comprising a therapeutically effective amount of galectin-1, galectin-3, or bFGF, or functional fragments thereof, to treat a dry eye disorder.
An ophthalmic composition comprising PDGF.
A pharmaceutical composition comprising a therapeutically effective amount of galectin-1, galectin-3, bFGF, or PDGF, or functional fragments thereof, to increase conjunctival goblet cell proliferation and/or secretion.
A method of increasing conjunctival goblet cell proliferation comprising contacting conjunctival goblet cells with a composition comprising galectin-1, galectin-3, bFGF, or PDGF, or functional fragments thereof.
A method of increasing conjunctival goblet cell secretion comprising contacting conjunctival goblet cells with a composition comprising galectin-1, galectin-3, bFGF, or PDGF, or functional fragments thereof.
A method of treating dry eye in an individual comprising contacting an ocular surface of said individual with a composition comprising galectin-1, galectin-3, bFGF, or PDGF, or functional fragments thereof.
Dependencies are inferred from the claim text.